Cure Parkinson’s and Van Andel Institute announce funding for a phase 1 clinical trial of low-dose lithium in Parkinson’s disease - vai.org/article/cure-parkin...
"Why study lithium in Parkinson’s?
Early preclinical data suggests that lithium at very low doses may be protective against the dopamine nerve cell (neuron) loss seen in Parkinson’s. In 2019, Guttuso conducted a small pilot study to test this potential link in people with Parkinson’s. The results suggested that lithium had a positive effect on trial participants. As such, in 2022, low-dose lithium was prioritized by the International Linked Clinical Trials (iLCT) program — a drug development initiative set up in partnership between Cure Parkinson’s and VAI to support the clinical evaluation of drugs with the potential to slow, stop or reverse Parkinson’s progression."